Press Releases Ono Pharmaceutical Co., Ltd.

Equities

4528

JP3197600004

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-09 am EDT			5-day change	1st Jan Change
2,274 ^JPY	-0.87%		-2.17%	-9.64%

Apr. 30	Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	RE
Apr. 29	US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ono Pharmaceutical : Notice regarding Differences in the Non-consolidated Financial Results between the Fiscal Year Ended March 31, 2024 and the Previous Fiscal Year	11:05pm	PU
Ono Pharmaceutical : Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals	Apr. 29	PU
PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono	Apr. 26	AQ
Ono Pharmaceutical : Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area	Apr. 25	PU
Ono Pharmaceutical : Announcement on Changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers	Apr. 05	PU
Ono Pharmaceutical : Announces Completion of Cancellation of Treasury Stock	Mar. 29	PU
Ono Announces General Sponsorship for the 'Theme Weeks' as Bronze Partner, at the Expo 2025 Osaka, Kansai, Japan	Mar. 28	AQ
Ono Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford	Mar. 25	AQ
Equillium to Present at the H.C. Wainwright Autoimmune and Inflammatory Disease Conference and the LD Micro Invitational Conference	Mar. 25	AQ
Ono Pharmaceutical : Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford	Mar. 22	PU
Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders	Mar. 15	AQ
Ono Pharmaceutical : Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders	Mar. 14	PU
Ono Pharmaceutical : U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	Mar. 11	PU
Ono Pharmaceutical : Enters into a License Agreement with NEX-I to Develop and Commercialize NXI-101	Mar. 05	PU
Ono Pharmaceutical Announces Status of Acquisition of Own Shares	Mar. 04	AQ
Ono Pharmaceutical : Announces Status and Completion of Acquisition of Own Shares	Mar. 04	PU
Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets	Feb. 20	AQ
ONO Enters into an Option and Collaboration Agreement with Numab to Develop Multi-specific Antibody NM49	Feb. 15	AQ
Bristol Myers Squibb - Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits after Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma	Jan. 23	AQ
Ono Pharmaceutical Co., Ltd. - Notice of Changes in Representative Directors	Jan. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ono Pharmaceutical Co., Ltd.

Equities

4528

JP3197600004

Press Releases

Filters